Rybelsus vs. Oral Wegovy vs. Compounded Oral Semaglutide
Three pill-based paths to GLP-1 treatment. One is FDA-approved for diabetes, one is the first FDA-approved oral GLP-1 for weight loss, and one is compounded. Here's when to pick which.
The Verdict
For weight loss specifically: Oral Wegovy at $149/mo is the clear winner — FDA-approved for the exact indication, backed by phase 3 data showing ~14% weight loss over 64 weeks. Rybelsus makes sense only if you have type 2 diabetes (it's not FDA-approved for weight loss and costs $950+/mo without insurance). Compounded oral semaglutide at $179–200/mo is a reasonable budget alternative if oral Wegovy isn't accessible, but lacks the FDA-approved oral Wegovy data.
For years, the only way to take semaglutide was to inject it. Weekly. With a needle. Understandably, a big chunk of potential patients opted out.
That changed in 2024 when oral semaglutide gained FDA approval for weight loss (Wegovy pill, launched late 2025). Combined with the pre-existing Rybelsus tablet (FDA-approved for diabetes) and compounded oral formulations from telehealth providers, there are now three pill-based paths to semaglutide treatment — each with very different regulatory, clinical, and pricing profiles.
The three contenders at a glance
| Feature | Rybelsus | Oral Wegovy | Compounded Oral |
|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Semaglutide |
| FDA-approved for | Type 2 diabetes | Weight loss | Not FDA-approved |
| Form factor | Tablet | Tablet | Tablet, drops, or lozenge |
| Daily or weekly? | Daily | Daily | Daily |
| Doses available | 3mg, 7mg, 14mg | 1.5mg, 4mg, 9mg, 25mg | Varies by provider |
| Cash price | ~$950/mo retail | $149/mo (low doses) | $179–200/mo |
| Clinical data for weight loss | Limited (off-label) | Phase 3, ~14% loss | Extrapolated |
Rybelsus: the original oral semaglutide
Rybelsus was FDA-approved in 2019 as the first oral GLP-1 receptor agonist. It's semaglutide in pill form, taken once daily, and it's indicated for type 2 diabetes management. It has not been FDA-approved for weight loss, though patients taking it for diabetes often experience weight reduction as a side effect.
What Rybelsus does well
- Long FDA track record. Six years of post-market data on safety and efficacy.
- Effective for blood sugar control in type 2 diabetes patients.
- Covered by most commercial insurance for diabetes indication, which brings copay costs down dramatically.
Where Rybelsus falls short
- $900–1,000/month cash price without insurance. That's ~6x the cost of oral Wegovy and compounded alternatives.
- Off-label for weight loss. Not FDA-approved for that indication, which means insurance coverage for weight-loss use is rare.
- Lower doses (7–14mg) than optimal for weight loss. Weight-loss trials of semaglutide used 2.4mg weekly injections, which far exceeds the daily equivalent of Rybelsus.
Oral Wegovy: the new FDA-approved option
Oral Wegovy is the commercial name for semaglutide in tablet form FDA-approved specifically for chronic weight management. It launched commercially in late 2025 after FDA approval, and Novo Nordisk is actively pricing it aggressively to capture the oral-GLP-1 market before Eli Lilly's competing oral product arrives later in 2026.
Pricing is remarkably consumer-friendly: $149/month for the 1.5mg and 4mg doses through June 30, 2026 (the 4mg dose increases to $199/month in September 2026). Higher doses (9mg and 25mg) cost $299/month, and Novo's 12-month subscription drops the ongoing monthly price to $249 for all doses.
What Oral Wegovy does well
- FDA-approved specifically for weight loss. The only oral GLP-1 with that indication.
- Phase 3 trial data backs it. Patients taking oral semaglutide achieved an average weight loss of approximately 16.6% over 64 weeks.
- $149/month is competitive with compounded oral alternatives. FDA-approved pricing at compounded levels is a first.
- No needles. Obviously.
Where Oral Wegovy falls short
- Strict administration requirements. Must be taken on an empty stomach with plain water, followed by a 30-minute waiting period before eating, drinking, or taking other medications. Failure to follow this significantly reduces absorption.
- The 4mg intro price expires September 2026 (jumps to $199/mo). The 9mg and 25mg maintenance doses are $299/mo without the subscription, so real treatment cost is higher than the headline.
- Slightly lower average weight loss than injectable semaglutide (16.6% oral vs. ~15% injectable — these are close and direct comparison is tricky, but clinically they're similar).
Compounded oral semaglutide: the budget alternative
Several compounded pharmacy telehealth providers offer oral semaglutide in various forms: tablets, sublingual drops, or lozenges. Providers include MEDVi, Synergy Rx, SHED, and Sprout Health (which recently added compounded oral tirzepatide tablets).
What compounded oral does well
- Format diversity. Drops and lozenges bypass first-pass metabolism, delivering medication through oral mucosa — potentially requiring lower doses. SHED leads on format variety (injectable, drops, AND lozenges).
- Often includes consultation and provider care in the monthly price, no separate fees.
- More affordable than Rybelsus by a huge margin — $179–200 vs. $950+.
- Month-to-month flexibility at most providers.
Where compounded oral falls short
- Not FDA-approved as a finished product. Prepared by 503A compounding pharmacies under state oversight.
- No dedicated clinical trial data on compounded oral forms. Drops, sublingual tablets, and lozenges lack the phase 3 studies that back oral Wegovy. Efficacy is extrapolated from injectable data.
- Dosing precision varies. Drops measured by dropper or lozenge potency can vary between compounding pharmacies.
- FDA scrutiny of compounded GLP-1 marketing is increasing (March 2026 warning letters targeted providers making unsupported efficacy claims about compounded products).
The 12-month cost comparison
| Path | Low Dose 12-Month | High Dose 12-Month |
|---|---|---|
| Rybelsus (cash) | $11,400+ | $11,400+ |
| Rybelsus (with insurance) | $300–1,200 | $300–1,200 |
| Oral Wegovy (12-mo sub) | $2,988 | $2,988 |
| Oral Wegovy (standard) | $1,788 (1.5mg only) | $3,588 (high dose) |
| Compounded (MEDVi) | $2,148 | $2,148 |
| Compounded (Synergy) | $2,400 | $2,400 |
Over a full year of treatment, oral Wegovy on a 12-month subscription ($249/mo) lands in the same price band as premium compounded options. That wasn't true in 2024 — oral Wegovy didn't exist yet — and it's the reason oral GLP-1 is suddenly the most interesting segment of the market.
Administration: the hidden differentiator
Compounded sublingual drops and lozenges don't have the empty-stomach requirement — they absorb through oral mucosa rather than the digestive tract. For patients who can't reliably manage the morning protocol, compounded sublingual formats may deliver more consistent real-world results than FDA-approved oral Wegovy, despite the regulatory gap.
What comes next
Eli Lilly has an oral GLP-1 product under FDA review, expected to launch later in 2026. When it arrives, it will likely put further price pressure on oral Wegovy. The compounded oral market will have to differentiate further (likely on format flexibility — drops and lozenges are hard for brand-name products to replicate).
For now, oral Wegovy at $149–249/mo is the clearest value proposition in the oral GLP-1 market. Compounded remains a viable budget alternative for those who want format flexibility or consultation bundling.
Sesame Care
Get an oral Wegovy prescription through a $29+ telehealth visit.
Check Sesame →Bottom line
If you want oral semaglutide for weight loss in April 2026, FDA-approved oral Wegovy at $149/mo is the right answer for most people. Rybelsus only makes sense if insurance covers it for diabetes. Compounded oral is a reasonable alternative if you want format flexibility (sublingual drops, lozenges) or bundled consultation — especially if you struggle with the empty-stomach timing requirement that brand-name oral semaglutide demands.